现在位置 >首页 > dubin98发表的所有文章
dubin98 ⁄ 发表于4年前 ⁄ 时讯速递, 进展交流 ⁄ [BMJ发表论文]:社区无症状新冠病毒快速抗原检测对新冠肺炎相关住院的影响已关闭评论
Research Impact of community asymptomatic rapid antigen testing on covid-19 related hospital admissions: synthetic control study ......
dubin98 ⁄ 发表于4年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: 补充维生素D与新冠肺炎的风险已关闭评论
Vitamin D Supplements and Risk of COVID-19 Findings from two large clinical trials show that increasing vitamin D levels in ad......
dubin98 ⁄ 发表于4年前 ⁄ 时讯速递, 进展交流 ⁄ [Lancet Respir Med发表论文]:抗C5a抗体治疗接受有创机械通气的重症新冠肺炎住院患者已关闭评论
ARTICLES| VOLUME 10, ISSUE 12, P1137-1146, DECEMBER 01, 2022 Anti-C5a antibody (vilobelimab) therapy for critically......
dubin98 ⁄ 发表于4年前 ⁄ 研究点评, 进展交流 ⁄ [JAMA发表论文]:新冠肺炎危重症后长期随访已关闭评论
Editorial  December 16, 2022 Long-term Follow-up After Critical COVID-19: REMAP-CAP Revisited Michael L. Barn......
dubin98 ⁄ 发表于4年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA研究来信]:俄勒冈波特兰和华盛顿西雅图2021年热浪与急诊科就诊的相关性已关闭评论
Research Letter  Climate Change and Health December 20, 2022 Association Between the 2021 Heat Wave in Portla......
dubin98 ⁄ 发表于4年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: ICU医务人员对临终决策相关法律的知晓已关闭评论
ICU Professionals’ Knowledge of End-of-Life Decision-Making Law There are laws regulating healthcare practice at the end of li......
dubin98 ⁄ 发表于4年前 ⁄ 研究点评, 进展交流 ⁄ [JAMA观察]:RNA测序作为诊断手段已关闭评论
JAMA Insights  Genomics and Precision Health December 16, 2022 RNA Sequencing as a Diagnostic Tool Shamika......
dubin98 ⁄ 发表于4年前 ⁄ 时讯速递, 进展交流 ⁄ [JAMA发表论文]:REMAP-CAP随机临床试验中新冠肺炎危重病患者的长期(180天)预后已关闭评论
Original Investigation  Caring for the Critically Ill Patient December 16, 2022 Long-term (180-Day) Outcomes ......
dubin98 ⁄ 发表于4年前 ⁄ 时讯速递, 进展交流 ⁄ [BMJ发表论文]:有症状的远端DVT患者接受利伐沙班治疗6周或3个月已关闭评论
Research Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis......
dubin98 ⁄ 发表于4年前 ⁄ 研究点评, 进展交流 ⁄ [ICU Management & Practice]: 输液后毛细血管再充盈时间的动态变化已关闭评论
CRT Kinetics After Fluid Infusion Peripheral tissue hypoperfusion is a strong predictor of poor outcomes in patients suffering......
×
腾讯微博